Sector News

Upstart Blade nabs BMS research executive as new R&D lead

August 21, 2017
Life sciences

Blade Therapeutics is looking to sharpen its focus after hiring Bristol-Myers Squibb’s former fibrosis research lead as its new EVP of research.

The biotech, which is working on antifibrotic (scarring) therapies, has appointed Maria E. Fuentes, Ph.D., to lead its antifibrotic programs in preclinical testing.

Blade’s flagship program, focused on a small molecule cysteine protease inhibitor, is expected to enter IND-enabling studies by year-end 2017.

Fuentes comes to the small, private biotech from Big Pharma Bristol-Myers, where she was group director of fibrosis discovery biology.

There, she was working getting into the clinic small molecules and antibody therapeutics for the treatment of fibrotic diseases, including interstitial pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH).

She’s also had a stint at oncology giant Roche, making this a big coup for such a small and embryonic biotech, and following the pattern in recent years of Big Pharma executives moving into smaller biotechs.

As with many biopharmas, including Gilead, Shire, Intercept and Genfit, BMS is looking to jump into the NASH space, which could be worth tens of billions of dollars in the next decade, to help treat liver scarring and other damage caused by a buildup of fat in the liver associated specifically with obesity.

Back in April, a phase 2 trial of its NASH candidate BMS-986036 met its primary endpoint, showing a reduction of liver fat, as it battles to be one of the first to market a new medication for the condition.

“We are excited to further expand our leadership team and to welcome an accomplished executive with a proven record of advancing promising candidates into the clinic,” said Blade’s CEO Wendye Robbins, M.D.

“We believe Maria’s expertise and insights will contribute greatly to the continued momentum of our lead development programs.”

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach